The Top 5 Biosimilar Articles for the Week of March 28

Hi, I’m Hayden Klein for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of March 28, 2022.

Number 5: Since the start of 2022, China’s National Medicinal Products Administration (NMPA) has made strides to increase access to biosimilar products for various rheumatic conditions, including 3 biosimilar approvals and 1 biosimilar receiving an expanded indication.

Number 4: A patient with ankylosing spondylitis (AS) and ulcerative colitis (UC) was diagnosed with polychondritis after taking an infliximab biosimilar, suggesting that patients with similar circumstances should be carefully monitored.

Number 3: Three biosimilars used for blood clot prevention secured public reimbursement status in British Columbia, one of several Canadian provinces that has a biosimilar switching program.

Number 2: While biosimilar uptake has been slow in the United States, a report showed that a utilization management program designed to promote biosimilar use can successfully increase uptake and reap significant savings.

Number 1: A trastuzumab biosimilar (HD201; Tuznue) demonstrated equivalence in efficacy and safety profiles compared with the reference product (Herceptin) in a phase 3 study of patients with erb-B2 receptor tyrosine kinase 2-positive (ERBB2+) breast cancer.

To read all of these articles and more, visit centerforbiosimilars.com.